2365 Nanoliposomal irinotecan (MM-398, nal-IRI) population pharmacokinetics (PK) and its association with efficacy and safety in patients with solid tumors based on the phase 3 study NAPOLI-1 and five phase 1 and 2 studies

Autor:	Antonio Cubillo, Joon Oh Park, Mark Wong, Javier Gallego, Bruce Belanger, Ik-Joo Chung, Bohuslav Melichar, Jen-Shi Chen, István Láng, Wen Wee Ma, Jung Sub Kim, B. S. Adiwijaya, E. Bayever, Tibor Csoszi, M. Smakal, M.W. Wenczl, Jun Suk Kim, K.M. Rau
Rok vydání:	2015
Předmět:	Irinotecan Cancer Research Oncology business.industry Phase (matter) Phases of clinical research Medicine In patient Population pharmacokinetics Pharmacology business medicine.drug
Zdroj:	European Journal of Cancer. 51:S458
ISSN:	0959-8049
DOI:	10.1016/s0959-8049(16)31281-3
Databáze:	OpenAIRE
Externí odkaz:	https://explore.openaire.eu/search/publication?articleId=doi_________::9b63815b04fc766c3e7d58058e40b98c https://doi.org/10.1016/s0959-8049(16)31281-3 Zobrazit plný text záznamu Full Text from ScienceDirect